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ABSTRACT 
Pre-clinical animal studies are mandatory before new treatments can be tested in clinical trials. 
However, their use in developing new therapies for sepsis has been controversial because of 
limitations of the models and inconsistencies with the clinical conditions. In consideration of the 
revised definition for clinical sepsis and septic shock (Sepsis-3), a Wiggers-Bernard Conference 
was held in Vienna in May 2017 to propose standardized guidelines on pre-clinical sepsis 
modeling. The participants conducted a literature review of 260 most highly cited scientific 
articles on sepsis models published between 2003 and 2012. The review showed, for example, 
that mice were used in 79% and euthanasia criteria were defined in 9% of the studies. Part I of 
this report details the recommendations for study design and humane modeling endpoints that 
should be addressed in sepsis models. The first recommendation is that survival follow-up should 
reflect the clinical time course of the infectious agent used in the sepsis model. Furthermore, it is 
recommended that therapeutic interventions should be initiated after the septic insult replicating 
clinical care. To define an unbiased and reproducible association between a new treatment and 
outcome, a randomization and blinding of treatments as well as inclusion of all methodological 
details in scientific publications is essential. In all pre-clinical sepsis studies, the high standards 
of animal welfare must be implemented. Therefore, development and validation of specific 
criteria for monitoring pain and distress, and euthanasia of septic animals, as well as the use of 
analgesics are recommended. A set of four considerations is also proposed to enhance translation 
potential of sepsis models. Relevant biological variables and co-morbidities should be included 
in the study design and sepsis modeling should be extended to mammalian species other than 
rodents. Additionally, the need for source control (in case of a defined infection focus) should be 
considered. These recommendations and considerations are proposed as “best practices” for 
animal models of sepsis that should be implemented.  
 
 
  
INTRODUCTION 
Sepsis is defined as life-threatening organ dysfunction caused by a dysregulated host response to 
infection (1). It is the most important cause of morbidity and mortality in patients admitted to 
intensive care units (ICU) with a significant cost impact in health care worldwide (2). Over the 
last decade, basic science research has identified fundamental molecular processes that are 
involved in the pathophysiology of the dysregulated metabolic, inflammatory and immune 
responses. However, despite this growth in fundamental knowledge and large investments in 
drug development and multiple clinical trials, no new effective therapies have been introduced to 
clinical practice. The treatment approach of the patient still relies on supportive care and 
antimicrobial agents (3). While we cannot underestimate inherent issues within clinical trials (4, 
5), there is increasing skepticism about the usefulness of animal models for predicting responses 
in clinical sepsis (6). One prominent reason of the inability of industry- and government-
sponsored clinical trials to validate results from the majority of animal studies should be 
attributed to methodological challenges in pre-clinical study design that poorly correlates with 
the clinical condition of sepsis. 
An important step to develop guidance on how to improve the quality and efficiency of 
pre-clinical studies was undertaken by the international Wiggers-Bernard Conference, which was 
held in May 2017 in Vienna. Prior to the meeting, participants conducted a literature review of 
the 260 most highly cited scientific articles on sepsis models published between 2003 and 2012 
as the basis for the conference discussions. The objective of the conference was to identify 
limitations of pre-clinical sepsis models and to propose a set of guidelines, defined as the 
“Minimum Quality Threshold in Pre-Clinical Sepsis Studies” (MQTiPSS; 7), to enhance 
translational relevance of the models. The main aim of this article is to propose a set of 
standardized guidelines for study design and humane modeling endpoints, with a major emphasis 
on clinical relevance and animal welfare. Concrete examples of experimental design, procedures 
and ethical endpoints are provided throughout these guidelines. It is expected that these 
guidelines will be used in conjunction with the more general and mandatory rules of a national 
legislation of a country in which research is conducted. It is important to note that these 
recommendations and considerations are proposed to assist in the design of the most appropriate 
animal sepsis model(s) and should be tailored to the specific hypothesis of the investigation.  
Overall, the Wiggers-Bernard initiative has led to the creation of three joint publications 
(8, 9) to serve as a MQTiPSS guideline for establishing the basic conditions in modeling of 
sepsis to improve their translational relevance. The current Part I paper makes specific 
recommendations preclinical models of sepsis within the areas of study design and humane 
modeling endpoints. The goal of the conference was to create quality thresholds for future 
studies so that findings in those two particular areas are more clinically applicable and the 
studies themselves are better comparable across laboratories and/or species. 
 
 
  
METHODS 
The Wiggers-Bernard Conferences on Shock, Sepsis and Organ Failure is an expert opinion 
exchange platform for international scientists organized by the Ludwig Boltzmann Institute of 
Experimental and Clinical Traumatology in the AUVA Research Center (LBI Trauma), Vienna, 
Austria (http://trauma.lbg.ac.at/en). The conference series was named after two outstanding 
scientists, one from the “New World” (Dr. Carl Wiggers) and one from the “Old World” (Dr. 
Claude Bernard) who devoted their careers to critical care medicine and experimental sciences. 
LBI Trauma is responsible for the topic selection while the Austrian Society of Advancement of 
Research in Shock and Tissue Engineering provides sponsorship for each Wiggers-Bernard 
conference. 
To address the deficits regarding management guidelines and standardization in the field 
of pre-clinical sepsis research, in May 2017 LBI Trauma organized the 9th iteration of the 
Wiggers-Bernard Conferences titled: “Pre-clinical Modeling in Sepsis: Exchanging Opinions 
and Forming Recommendations”. The key goal of the conference was to create publishable 
material that identifies essential elements that should be included in pre-clinical sepsis studies 
and defined by the MQTiPSS descriptor (10). A total of 31 experts from 12 countries, including 
five members of the Sepsis-3 definitions task force (1), were invited to participate in the 
initiative based on their experience in experimental, clinical and translational research.  
The initiative consisted of three phases: a) three-months preparatory phase where 
participants performed a systematic review of the 260 top cited publications from 2003-2012 and 
identified the key modeling topics to be discussed, b) discussions in Vienna (two days), during 
which the participants drafted a list of guidelines and c) post-conference refinement of the 
created works. 
The preparatory phase review was conducted using ISI Web of Knowledge database 
(using the query: “sepsis model”). The 260 most cited papers (the citation range 50-743; 
referenced over 29,000 times in aggregate) featuring a total of 374 animal studies were 
identified. The time frame was subjectively defined as 10 consecutive years beginning with 2003 
as the year of publication of the second iteration of sepsis definitions (11, 12). The results of that 
survey pertinent to the topics covered in this paper are collated in Tables 1 and 3. Since the first 
analysis showed that mice were used in 79% of the 2003-2012 papers, a secondary smaller 
search was performed and included all 2013-2017 studies (total of 190; irrespective of the 
number of citations) with mouse sepsis models only (using the query: “sepsis AND mice”); to 
compare to selected endpoints reviewed in the main review that spanned 2003-2012. Both 
analyses were used during the meeting. Overall, the preparatory phase aimed at identification of 
the most important concepts in animal sepsis modeling to be addressed at the Viennese Wiggers-
Bernard Conference. All participants were allocated into six specific thematic Working Groups 
(WGs): 1) Study Design, 2) Humane Modeling, 3) Infection Type, 4) Organ Failure/Dysfunction, 
5) Fluid Resuscitation and 6) Antimicrobial Therapy Endpoints.  
During the conference phase, each WG separately drafted a set of guideline points that 
were subsequently subjected to general discussion and streamlined either for further refinement 
in WGs or dismissal (day 1). After improvements, the proposed points were subjected to voting 
by all participants to reach consensus (day 2). Overall, the Wiggers-Bernard Conference 
participants reached consensus on 29 points; 20 at “recommendation” strength and 9 at 
“consideration” strength (the WG-1/2 points are listed in Tables 2 and 4). Following the format 
used by the Sepsis-3 task force (13), at least 2/3 (over 65%) of the votes were required for 
approval of a proposed point. All consensus points were reached either unanimously or with no 
more than 2 abstentions per point (i.e. Recommendation 8). The “recommendation” strength 
indicates virtually unanimous agreement among the 31 participants, regarding both the content as 
well as the need for rapid implementation. Issues that require additional discussion (in the 
opinion of the participants) before final recommendations could be made were classified as 
considerations.   
During the post-conference phase, the arguments to be included in the final MQTiPSS 
publications were finalized through teleconferences and electronic-based discussion among WGs 
using a modified Delphi method. Finally, a writing committee (formed at the conference) 
together with all participants developed an Executive Summary for MQTiPSS (7) and three full-
size publications (8, 9). Each (of the three) publication focuses on two related WGs; the current 
Part I paper provides detailed discussion on the guideline points for Study Design and Humane 
Modeling Endpoints. 
  
CHAPTER 1: STUDY DESIGN 
An ideal pre-clinical animal model should accurately reproduce the human disease. While the 
complexity of human sepsis and its phenotypes precludes creation of a single ideal model, a 
standardization of defined model systems appears feasible and should be considered (14). We are 
convinced that adequately designed animal models of sepsis and other diseases can be useful 
tools, including the discovery and development of new therapeutic interventions (15). Therefore, 
it is important to elucidate the criteria, which must be fulfilled to obtain meaningful animal 
results for human translation. 
The pre-meeting review of the top-cited experimental animal studies (2003-2012) 
provided evidence of bias and numerous methodological limitations of animal research in sepsis. 
As summarized in Table 1, we identified several challenges in the study design, experimental 
conduct and reporting that can impede successful translation of the findings from animal 
research to human patients. For example, although survival was reported as a primary endpoint 
in 43% of the animal sepsis studies, the vast majority of experiments had a brief follow-up. 
Given the frequent late mortality and long-term sequelae in septic patients (16), such a brief 
monitoring in many pre-clinical studies is not justified by the prolonged course of clinical sepsis. 
Another design shortcoming is the mismatch of therapeutic interventions between animal studies 
and septic patients. Only in 36% of the animal studies the experimental therapy was given after 
the onset of sepsis. In most cases, the timing of those interventions was chosen subjectively and 
not dictated by symptoms and/or disease severity. Of concern is also a low inclusion of 
biological variables and co-morbidities in the study design; only 5% of the reviewed studies 
featured any type of comorbidity. While the choice of healthy, inbred animals of same sex, age 
and weight limits the baseline variability in pre-clinical models, it simultaneously prohibits 
replication of the heterogeneity encountered in the patient population. Promising pre-clinical 
findings obtained in those simplistic models should be validated in more complex experiments 
that take into consideration modifying risk factors of morbidity and lethality. 
The above study design shortcomings are additionally aggravated by yet another 
hindrance: insufficient reporting of the methodological details. In the reviewed top-cited papers, 
we identified several inadequacies in describing details on animals, methods and materials 
employed in the experiments - all of which can potentially confound the interpretation of the 
study results and impede experimental reproducibility. Inadequate reporting also prohibits 
verification whether proper tools for reducing bias were employed, i.e., randomization for group 
allocation and blinding of outcome assessment. Scientific rigor demands that scientific reports 
provide accurate and sufficient details on the methodology to enable replication of the findings 
by other investigators to prove their validity (17). For a successful translatability of animal 
models, it is paramount that rigor is observed in pre-clinical sepsis research. 
 
Specific recommendations for Study Design 
The conference discussed several specific recommendations for pre-clinical models of sepsis. In 
the current Part I paper, the recommendations and considerations from the Study Design 
Endpoints working group are numbered consecutively beginning with recommendation 1 and 
continue in the next chapter (Humane Modeling Endpoints) and the two subsequent companion 
papers (Part II and III). 
 
 
Recommendation 1: Survival follow-up should reasonably reflect the clinical time course of 
the sepsis model.  
Although animal models will never fully recapitulate human illness, it is paramount to adapt 
them to reflect the changing nature of the studied disease. Historically, animal sepsis models 
employed a relatively high mortality rate (18), which reflected the high lethality of multiple 
organ failure (MOF) (19). As a result of multiple international initiatives to improve the 
implementation of evidence-based medicine in the ICU, the epidemiology of sepsis has evolved: 
early in-hospital mortality has decreased and many high-acuity patients survive, generating a 
new patient phenotype of “chronic critical illness” (CCI) (20). For example, recent prospective 
longitudinal cohort studies of sepsis/septic shock revealed that early inpatient mortality from 
refractory shock and MOF is now below five percent (21, 22). Other studies have demonstrated 
that the initial 28-day sepsis mortality is approximately 20 percent, but this increases to nearly 35 
percent at 6 months (16). Additionally, the long-term CCI morbidity can be dismal - after 6-
months, a significant portion of these patients have poor function and cognition and are 
discharged to non-hospital inpatient facilities rather than home (16, 21, 22). Of the latter, 
mortality is almost 40 percent at 6-months (21, 22). 
The clinical need for a long-term focus is poorly met by typical short-term animal sepsis 
studies. For example, only 10% of the studies we reviewed employed monitoring exceeding 14 
days (Table 1). Thus, we recommend that the survival follow up should reasonably reflect the 
clinical time course of the infectious agent used in the model or the patient population being 
studied. For example, a shorter monitoring period for meningitis would be appropriate given the 
acute clinical course of the human disease (23). There are appropriate abdominal, urinary, and 
pulmonary models with high early mortalities that can study important aspects of the early 
mammalian response to severe infection (18). However, if the research goal is to replicate the 
clinical trajectory of most sepsis patients in developed nations, a longer monitoring period is 
more appropriate as acute mortality with sepsis is becoming rare. Researchers need to develop 
models of persistent chronic immuno-dysregulated conditions after sepsis, as this is now the 
predominant human phenotype (24-26). Although rarely performed, due to complexity and costs, 
modeling of chronic sepsis that features persistent immuno-inflammatory deficits and late 
mortality is achievable (27, 28). Such a modeling shift, however, requires a concurrent 
development of humane endpoints appropriately tailored for that type of animal sepsis research 
(see Chapter 2). 
It is still unclear what the equivalent number of hours or days in a rodent (most 
commonly used species) are when compared to human time points, as there is a temporal 
mismatch between the species (18). For example, 1 hour in mice/rats is equivalent to 
approximately 40 hours in humans (assuming the lifespan of 2 versus 80 years). However, the 1 
hour versus 40 hours recalculation formula should not be used reflexively as acute response 
between rodents and man bear many temporal similarities. For example, intravenous 
lipopolysaccharide (LPS) stimulation in human volunteers (29, 30), mice (31), rats (32) and pigs 
(33) leads to a virtually identical time-based response in the acute release of circulating 
inflammatory cytokines. Although some researchers have determined certain equations to relate 
different species (i.e. mouse with man) (34, 35), variations persist when considering weaning, 
puberty and senescence (34, 36). In addition, there are other differences in the timing and 
magnitude of the sepsis response in both species (18). Therefore, researchers may never be able 
to definitely state, “one week after cecal ligation and puncture (CLP) in a mouse is the same as 
one month for a septic human in the ICU.” However, it is unlikely that a murine model with 80-
100% mortality in the first 48-72 hours accurately represents the biology of patients who become 
CCI, or subsequently develop the Persistent Inflammation Immunosuppression Catabolism 
Syndrome (21, 22). 
Recommendation 2: Therapeutic interventions should be initiated after the septic insult 
replicating clinical care. 
In order to mimic the clinical scenario, it is instrumental to administer any therapeutic agent to 
be tested after the induction of sepsis. Animal models have been utilized for the initial testing of 
potentially effective therapies for decades but one can conclude that there is a large inconsistency 
between animal and human trials (37, 38). The application of pretreatment instead of 
posttreatment has been an important shortcoming in numerous studies that has hindered the 
extrapolation of animal data to the patient population (37, 38). While the onset of experimental 
sepsis is known in animal models, patients never present at “time zero” and their infection 
develops for a significant time prior to clinical identification. Furthermore, it should be 
emphasized that sepsis itself will have a profound impact on the metabolic, cardiovascular, 
immunological, and other responses in an animal model (24, 26, 37). These, in turn, can have 
considerable impact on the therapeutic intervention that is evaluated. In this respect, it is 
essential to extrapolate treatment-related findings from the specific models towards the specific 
clinical scenario they attempt to recapitulate (e.g., CLP representing polymicrobial peritonitis).  
 There are some points of contention concerning this recommendation. There are many 
examples of pharmacological agents, which have been positively evaluated in an animal model 
of sepsis using a proper post-treatment approach, but which yielded negative results in large 
human clinical trials (39). Well documented examples include the use of recombinant tissue 
factor pathway inhibitor (tifacogin) (40, 41), anti-Toll like receptor (TLR)-4 strategies (42-44) 
and interleukin-1 receptor blockade (45-46). Also, the issue of post-treatment is not simply time, 
but more the evolution of organ dysfunction and the processes that could result in death. 
Compared to patients, these trajectories can be divergent in animal models. Thus, a therapeutic 
intervention should not be solely based on the vector of time but should also account for the 
phenotype of the sepsis pathophysiology at the time of the intervention. 
This further emphasizes the point that this specific recommendation is just part of the 
presented broader set of recommendations aiming to better mimic the clinical scenario and 
enhancing the translational power of the sepsis model used. In fact, it would not be entirely 
surprising if the above-mentioned treatment strategies will eventually be demonstrated to work in 
more precisely defined subsets of septic patients (37, 47). In addition, it should be acknowledged 
that - depending on the objective of any particular study - pretreatment can be reasonable, e.g. in 
multi-hit models simulating secondary infections or in a setting of prophylaxis. Also, pre-
treatment is valuable if the goal is to understand disease pathogenesis rather than to predict 
treatment efficacy. These points, however, should be explicitly mentioned in the description of 
the methods. 
In summary, from a clinical translation standpoint, when testing novel therapies, 
treatments should mimic the clinical management of the patients, i.e. given after the onset of 
sepsis. Efficacy of experimental drugs should be compared to or used in addition to minimum 
standard care of sepsis, i.e. fluid resuscitation and antibiotics, as is outlined in Part III paper (9). 
 
Recommendation 3: We recommend that the treatment be randomized and blinded when 
feasible.  
Methodological shortcomings in animal experimentation introduce bias and may distort study 
conclusions. Systematic analyses of pre-clinical studies demonstrate shortcomings in 
randomization and blinding. For example, in 2009, the National Centre for the Replacement, 
Refinement and Reduction of Animals in Research (NC3Rs) reported that only 12% of studies 
performed randomization and 14% used blinding (out of 271 surveyed studies) (48) and similar 
deficiencies were reported by others (49, 50). While we did not determine 
randomization/blinding in our review of pre-clinical sepsis studies, others reported difficulty in 
appraising the risk of bias secondary to lack of randomization, allocation concealment and 
blinding (51). In the critical care field, Ramirez et al. (50) demonstrated presence of 
randomization only in 22% and blinding in 33% of examined cardiovascular model studies. 
Although it cannot be excluded that some of those studies used randomization/blinding without 
disclosing it, the lowest use of randomization (17%) was reported in mouse-based experiments 
(50) – the species whose size enables repetitive high-power testing.  
 Lack of proper randomization and blinding in critical care studies may overestimate 
treatment benefits both in human trials (52) and animal models (53). An analysis of abstracts 
presented at the annual emergency medicine meetings revealed that non-randomized and/or 
unblinded studies were more likely to report positive outcomes (odds ratio 5.2; 95% confidence 
interval, 2.0-13.5) (54). Failure to randomize and/or blind were key factors behind the inability to 
reproduce landmark pre-clinical findings in anti-cancer, cardiovascular and amyloid lateral 
sclerosis therapies (55-56). 
 Both randomization and blinding can be implemented, although some constraints in 
blinding are unavoidable and must be recognized in some study types, e.g. when testing new 
devices. Promising animal treatment studies often constitute a launching platform for human 
testing. To eliminate dissemination of misleading data, the methodological rigor of 
randomization and blinding should be applied in pre-clinical experiments, whenever study design 
allows that. As an ultimate goal, to strengthen the translation bridge between bench and bedside, 
the pre-clinical testing should approach the quality of clinical trials. The recent multicenter pre-
clinical randomized controlled trial verifying efficacy of anti-CD49d treatment against stroke 
(57) demonstrates that this is feasible and could be adapted for sepsis research. 
Recommendation 4: Provide as much information as possible (e.g. ARRIVE guidelines) on 
the model and methodology, to enable reproducibility.  
Although experimental reproducibility is key in evidence-based science, pre-clinical studies (17) 
are burdened by methodological under-reporting with estimates for irreproducibility ranging 
from 75% to 90% (58). Holman et al. (59) showed that under-reporting precluded identification 
of animal attrition in over 60% of articles in stroke and cancer. Publication analysis of three 
high-impact critical care journals revealed poor methodological reporting of study design and 
ethical intervention in animal studies (60, 61). Poor transparency impedes replication and cross-
comparison of animal studies including sepsis. The NIH has recently launched a training 
initiative to address this problem (www.nih.gov/research-training/rigor-reproducibility). 
Our recommendation may appear redundant in view of various existing guidelines 
promoting transparency reporting, e.g., Animals in Research: Reporting In Vivo Experiments 
(ARRIVE) (62), journal checklists (e.g. EMBO Press Checklist) (63) and Transparency 
Openness Promotion (TOP; https://cos.io/top) initiative by Nature. Compliance to these 
guidelines is key for reproducibility. Unfortunately, using the ARRIVE example, the recent 
analysis of pre-clinical studies demonstrated their low compliance with the ARRIVE and poor 
improvement in reporting quality (64, 65). The underlying reasons are mixed: 
disinclination/neglect of the authors to provide complete methodology, space limitations by the 
journals, and lax enforcement at the stage of peer-review process and publication. It is possible 
that guidelines specifically tailored to individual research areas and endorsed by their 
professional bodies will have more impact and enable better enforcement. Sepsis research should 
follow the existing examples: the American Heart Association released recommendations on 
design, execution and reporting of animal studies in atherosclerosis (66) and the Stroke journal 
has recently issued a second checklist edition for experimental stroke models (67). The latter 
example demonstrates a success of such a focused approach: reporting standards improved in 
animal studies submitted to Stroke after implementation of the first checklist (68). 
Implementation of best reporting practices should also include full disclosure of the originally 
posited study objective(s) to communicate the rationale behind the experimental design. Use of 
the journals’ supplementary section to provide a detailed methodological description should be 
encouraged. This absence of detail is not trivial; despite widely endorsed CONSORT guidelines 
(www.consort-statement.org), analysis of 67 clinical trials by COMpare Trial Project identified 
severe discrepancies between final clinical trial reports and their entry protocols (e.g. 357 
unplanned outcomes added, 354 planned outcomes not reported) (69). The pre-clinical field is 
much less controlled for such inconsistencies and more efforts should be made to improve the 
reporting practices. The high-quality reporting standards will not be achieved without strong 
enforcement mechanisms. 
 
Consideration a) Consider replication of the findings in models that include co-morbidity and 
or other biological variables (i.e., age, gender, diabetes, cancer, immunosuppression, genetic 
background and others).  
Advanced age, chronic obstructive disease, cancer, chronic renal disease, chronic liver disease, 
diabetes and immunosuppression constitute known risk factors in sepsis (70) and influence the 
degree of infection/injury as compared to the same insults in healthy young adults (70-76). While 
young mice are valid for specific types of basic science sepsis research, the results of such works 
are limited in their ability to be directly translated to septic humans (4, 18). In pre-clinical 
studies, the use of healthy inbred animals of the same sex, age and weight is frequent as it limits 
baseline variability (18). However, human patients are ‘outbred,’ have variable ages, gender and 
weight, individual comorbidities, and have different causes of sepsis. All of these will affect the 
host response and influence the morbidity and mortality of the septic patient. Host genetic factors 
are also relevant to the variability in sepsis susceptibility and outcomes (70). 
         Sepsis pathophysiology is extremely complex (26, 37, 77, 78). Although there is value in 
studying the mammalian response to severe infection in standardized rodent models, researchers 
should consider repeating their work in modified animal models that more closely recapitulate 
the human condition/variability prior to directly translating their findings to patients (18, 37). We 
encourage development of a large family of sepsis models that represent options in which sepsis 
phenotypes may present and fluctuate, for example, validating the work in a model that features 
a modifying risk of morbidity and lethality (e.g., aging, gender, diabetes, cancer, 
immunosuppression, genetic background). This also includes two-hit models in which sepsis is 
modified by a defined critical care condition (e.g., trauma) and/or secondary infection (79-81). 
For sepsis, age constitutes one of the key modifiers given the demographic characteristic of 
septic patients (typically >65 years old) and associated age-related comorbidities (82). Yet, a 
review of pre-clinical sepsis studies reported that less than 1% of studies employed appropriately 
aged animals (83). Regarding biological variables, outbred mice feature an immune system that 
is more comparable to humans, providing a tool to improve the translatability of sepsis research 
to human patients (84). Furthermore, non-rodent sepsis models in species whose biology is more 
similar to humans can be conducted to determine how applicable rodent work is to human 
biology (18). Based on our current understanding of sepsis pathophysiology, failure to properly 
integrate the above-mentioned factors into experimental designs of animal studies likely limits 
the translational potential of the pre-clinical results. 
 
Consideration b) In addition to rodents (mice and rats), consider modeling sepsis also in other 
(mammal) species. 
Due to the varied nature of sepsis, it is unlikely that models that involve one species will be able 
to mimic all aspects of the clinical and biological complexity of the disease that are encountered 
in humans (37). Therefore, the authors believe researchers should consider modeling sepsis in 
other mammalian species in addition to rodents. This consideration does not intend to compel 
investigators into performing repetitions of their studies across multiple species, especially if 
studies in rodents are well validated and government agencies (e.g., United States Food and Drug 
Administration (FDA) and European Medicine Agency (EMA)) do not require such a step. 
However, as for most basic science research, it is important to note that rodents are by far the 
most commonly used species for modeling sepsis (85). The reasons for robust use of mice and 
rats include: high fecundity; accelerated life cycle; low maintenance; well-characterized genome; 
inbred, outbred and transgenic strains; widespread availability as well as reagents used to study 
them; and the creation of ‘humanized’ mice (18). Our literature review (Table 1) shows that 79% 
of the studies on sepsis used mice and 94% used rodents. However, we need to consider that 
rodent models have several significant inherent limitations (85, 86). For example, mice have a 
higher resistance to the systemic inflammatory response associated with infection (18); due to 
the high resilience of mice against infections, 10E
7-9
 E. coli or S. aureus are needed to affect 
mice; this would correspond to 3.5x10E
12
 bacteria in humans (87, 88). In this context, a rabbit 
model may be more appropriate for S. aureus-induced sepsis (89).  Another example is the 
blunted response of mice to bacterial products, such LPS – the lethal dose in mice is 
approximately 1,000 times greater than the estimated lethal dose in humans (18). Other 
differences between humans and mice also need to be taken into consideration. The composition 
of murine leukocytes in whole blood is dissimilar to that of adult humans, for both innate and 
adaptive immunity (18) and the two species have mismatching temporal response patterns to 
infection (6).  
Thus, a mouse does not necessarily represent the complex systemic background of the 
septic response in humans and narrow (i.e. in a single species) pre-clinical testing of given 
phenomena could mask numerous effects (18). Given these concerns, validation of pre-clinical 
sepsis findings in more than one single species can enhance its translational potential. This can 
include rabbit, porcine, bovine and non-human primate models (85, 90). Furthermore, other 
species may be more appropriate in specific sepsis models due to their physiology and 
pathophysiology being more similar to humans. It should be noted, though, that to date these 
animals have also not been successful in the clinical application of biological response modifiers 
in humans (18). Finally, cost and the absolute necessity for the humane treatment of these 
research animals can limit what can be conducted by individual laboratories regarding animal 
sepsis research (18). However, those issues should not preclude attempted advancement or 
optimization of animal sepsis research modeling. 
Consideration c) Consider need for source control. 
“Ubi pus, ibi evacua”; when there is a collection of pus in the body causing sepsis the evacuation 
of it is the most important aspect of its management. The Surviving Sepsis Campaign guidelines 
recommend that source control should be implemented as soon as medically and logistically 
practical after the diagnosis is made (3). Consequently, prompt removal of intravascular access 
devices that are a potential source of sepsis is recommended after other vascular access has been 
established (3). In humans, source control within 6 to 12 hours after diagnosis seems to be 
sufficient in most cases (3, 91, 92). The sepsis guidelines mention the following foci of infection 
readily amenable to source control: intra-abdominal abscesses, gastrointestinal perforation, 
ischemic bowel, cholangitis, cholecystitis, pyelonephritis associated with obstruction or abscess, 
necrotizing soft tissue infection, other deep space infection (e.g., empyema or septic arthritis), 
and implanted device infections (3). How do these insights translate to the design of a pre-
clinical model of sepsis? 
Most literature on this subject is derived from the CLP model. The ligated and punctured 
cecum can be excised at various intervals to serve as a source control model of sepsis (93). 
Source control measurements in that model have been associated with resolution of the 
inflammatory process (94).  Nonetheless, it should be acknowledged that source control adds 
complexity to the model which could interfere with other endpoint parameters. In addition, the 
timing of excision and drainage is of importance. An early excision for source control can be 
associated with no mortality, while delayed intervention can lead to increased mortality or no 
effect on the clinical course. In summary, the committee recommends researchers to consider the 
use of source control in an animal model of sepsis, when appropriate, in order to be consistent 
with the management of human sepsis.  
  
CHAPTER 2: HUMANE MODELING  
Our desire to establish humane endpoints relates to our aim to promote good care and welfare 
practices in pre-clinical sepsis experimentation worldwide. The current rules for experimental 
animal welfare in sepsis studies differ among countries, although these differences are declining 
as more U.S. and international organizations are voluntarily seeking accreditation by Association 
for the Assessment and Accreditation of Laboratory Animal Care International (AAALAC). 
Furthermore, many journals are going beyond local ethics committee approval and are adhering 
to animal welfare recommendations promulgated by the Guide for the Care and Use of 
Laboratory Animals (8th edition), published by the National Research Council (USA) (95). 
Given that animal sepsis models display a relative high burden of suffering, precise monitoring, 
effective analgesic control and death-as-an-endpoint are frequently discussed. The present paper 
aims to instigate a long-term process that eventually leads to an optimal standardization of 
humane practices in animal sepsis modeling. For example, the emphasis should be on improving 
the ability to detect indicators of sepsis-related morbidity and mortality, and on challenging 
assumptions that mortality as an endpoint is ‘inevitable’, yet retaining compatibility with human 
sepsis studies, which continue to rely on the death endpoint and include patients with 
comorbidities. Numerous humane endpoints can be refined and perceptions about the ability to 
predict impending death are constantly changing due to technological improvements (e.g., 
determinations of biomarkers from small blood samples, non-invasive microchip monitoring of 
vitals). 
         Humane endpoints in sepsis are best used in conjunction with prospective planning for 
their use (i.e. not ad hoc to address welfare concerns as they arise). In designing an experiment, 
the researcher should a) clearly specify the expected experimental outcome (and efficacy 
endpoints for drug intervention studies), b) adequately justify the needs for a given outcome to 
prove the hypothesis and c) precisely delineate all tools employed for eliminating/reducing 
animal suffering. Our review of the 260 pre-clinical sepsis studies demonstrates that the welfare-
related elements are typically not reported (Table 3). For example, in over 90% of the reviewed 
studies no euthanasia criteria were defined/mentioned, while in less than 10% of the studies the 
use of analgesia was disclosed. Specific criteria that will allow recognition of when the 
experimental outcomes have been met should be identified when planning the study and non-
invasive techniques including imaging, behavioral
 
or physiological monitoring (e.g., via 
biotelemetry) can be useful in reaching this goal. It is also important to recognize that it is not 
always necessary for an animal sepsis model to share all features of the human sepsis 
pathophysiology. It may be sufficient that the animal model recapitulates one specific but 
relevant element of the human disease (e.g., cardiac dysfunction, acute lung or kidney injury). 
Overall, development of uniform and justifiable humane endpoint guidelines for pre-clinical 
sepsis experiments would aid in facilitating approval for necessary and clinically translatable 
studies with professional regulators as well as public opinion concerned with the ethical use of 
animals in research. 
 
Specific recommendations for Humane Modeling 
The conference discussed several specific recommendations for pre-clinical models of sepsis to 
advance the use of these models. The following recommendations and considerations from the 
Humane Modeling Endpoints working group are numbered consecutively from the preceding 
chapter and start with recommendation 5. 
Recommendation 5: The development and validation of standardized criteria to monitor 
the well-being of septic animals is recommended.  
A laboratory animal should be able to exercise natural behavior without experiencing distress. 
Such an environment can be provided for rodents and rabbits (96, 97), but not as easily for large 
mammals (98) and non-human primates (99). Majority of experimental procedures impair the 
animal well-being, but sepsis studies produce a significant degree of suffering. To classify the 
magnitude of the impact on well-being, development and validation of monitoring criteria for 
septic animals is necessary (100, 101). The selected well-being criteria need to be frequently 
monitored and should encompass animal behavior as well as clinical examination (100, 102). 
Few scientific publications propose specific evaluation protocols (103, 104); they focus on the 
assessment of the sepsis severity rather than the animal welfare itself. For example, a mouse 
clinical assessment score for sepsis (M-CASS) allows staging the severity of pneumonia (103) 
by evaluating several clinical and behavioral parameters. Our literature search failed to reveal 
any standardized scores for the monitoring of animal well-being and/or sepsis progress in large 
mammals. 
Modern technology can enhance the non-invasive monitoring capability in animal 
experimentation. Implantable biotelemetry devices are used for monitoring physiology and, in 
sepsis, disease severity (e.g,. heart rate, body temperature and mobility) in mice (105-107). 
Recently, Lewis et al. (108) demonstrated a large-scale utility of biotelemetry monitoring for 
fluid resuscitation and antimicrobial treatment in CLP mice. In vivo wireless monitoring of 
cardiovascular endpoints has been successfully tested in pigs (109), dogs and non-human 
primates (110). Continuous body temperature monitoring using non-invasive infrared light is 
another alternative (111). However, disadvantages exist: biotelemetry-devices are relatively 
expensive, require a surgical intervention, which may alter the response to the sepsis insult, and 
might necessitate specific housing (112). Alternative monitoring techniques such as 
echocardiography (113), blood pressure and heart rate assessments (114) are also possible but 
require expertise and additional procedures for the animals, such as anesthesia and restraint. 
Initial well-being assessment criteria can be simple; it is important to first instigate a 
positive reception for such practices and create a framework that enables its quality 
standardization and further technical development. As the first step, we recommend focusing on 
systematic recordings of a) behavioral changes (e.g., food intake, vocalization, mobility, social 
interactions) and b) clinical symptoms (e.g., body weight, respiratory and temperature changes) 
(103, 104, 115). Pre-clinical laboratories already employ many of these endpoints and their 
arrangement into a standardized well-being protocol should not be arduous. The next step will 
require adjustments of the evaluation criteria to meet the ‘welfare demands’ of more complex 
sepsis models (e.g., co-morbidity, two-hit models, chronic sepsis). Comorbidities typically alter 
both behavior and clinical parameters: e.g., an overweight diabetic mouse is less active compared 
to a healthy mouse (116) and weight gain in a chronically septic mouse is a sign of recovery, not 
deterioration as in acute sepsis (117). A routine use of standardized well-being scores in septic 
animals can serve as additional efficacy or adverse effect variable to complement non-mortality 
secondary endpoints such as assessment of organ dysfunction. Thus, monitoring of well-being 
scores can be tailored to the respective sepsis model to account for variations in pathophysiologic 
responses secondary to changes in environment, strain, gender and co-morbidities. 
Recommendation 6: The development and validation of standardized criteria for 
euthanasia of septic animals is recommended (exceptions possible).  
Current legislation for animal experimentation in the United States (95), Japan (118) China 
(119), and European Union (EU) (120) allows but discourages inclusion of death as an endpoint. 
Some EU countries (e.g., the United Kingdom) and individual research institutions (e.g., Vlaams 
Instituut for Biotechnologie, Belgium) have voluntarily implemented ban on using death as 
endpoint. In critical care animal and human studies, death remains a frequently used parameter; 
its replacement with surrogates is not always justified and may be misleading. The key concern 
is that “preemptive” euthanasia (i.e. dictated by the ban) or euthanasia based on commonly 
utilized humane endpoints is either uninformative or the outcome assumptions can be imprecise. 
For example, Nemzek et al. (121) demonstrated that only 56% of CLP mice with a body 
temperature below 30°C died. Thus, liberal euthanasia cut-offs in pre-clinical sepsis can distort 
data subsequently impairing translatability of animal findings to patients (115, 121). 
Additionally, predictive imprecision of surrogate endpoints may preclude identification of 
unexpected life-saving effects by some therapies. Currently, many investigators assume their 
favorite surrogate endpoint, such as reduction of organ dysfunction predicts an increase in 
survival; such an approach should not be followed until a given surrogate marker has been 
validated to precisely predict death or long-term survival.   
The above controversies underline the need for developing precise and standardized 
criteria for euthanasia in sepsis research (122) to ensure an acceptable combination of 
experimental design quality and ethical practices. Development of defined cut-off(s) for 
euthanasia in septic animals is inherently linked with R-5 given that the animals must first 
deteriorate (i.e. decreased well-being) to the moribund state (defined by R-6). The two R-5 and 
R-6 recommendations should be viewed as a continuous monitoring paradigm transitioning from 
a) a set of behavioral/clinical descriptors (R-5) in non-lethal sepsis to b) a precise decision-
making tool (R-6) for euthanasia in animals approaching the moribund state. Thus, the key 
welfare issue predominantly arises from the distress preceding the moribund state; it is currently 
unclear to what extent (if at all) unresponsive and/or comatose animals experience pain (122). 
Euthanasia of animals that reach “a dying state” eliminates spontaneous deaths but does not 
eliminate their distress experienced during progression to that state (123, 124). In the ethical 
context, endpoints identifying moribund animals can never be considered humane enough (115); 
they constitute a trade-off between a need for investigative confidence and relief from 
unnecessary suffering. A tight synchronization/use of both R-5 and -6 should enhance the latter 
without jeopardizing the former. A reliable R-5 (well-being) score will automatically strengthen 
the informational quality and precision of R-6. This, in turn, will potentially facilitate 
identification and implementation of the irreversible “dying state” cut-offs at earlier stage(s) of 
sepsis. 
In the technical context, the existing criteria for euthanasia in septic rodents (103, 104, 
121) and pigs (124) are typically based on changes in behavior, body weight and temperature; 
telemetric devices can further refine the above approach (105, 109, 110). Blood biomarker 
measurements are another alternative as outcome predictor in septic mice (125, 126). Compared 
to the clinically-based criteria, biomarkers are advantageous as relatively early predictors of 
mortality, thus preventing the deterioration of animals to the moribund state. However, they 
require repeated blood sampling (127), which produce distress (128). Additionally, current 
biomarker-based assays are not completely precise (126, 129), are technically challenging and 
preclude the monitoring of late sepsis. 
Several elements require consideration for creation of effective pre-clinical euthanasia 
criteria. First, non-invasive clinical and behavioral descriptors (as discussed in R-5) appear to be 
a good starting platform. Recent works in mice provide several candidates for defining the 
moribund state (121) and demonstrate how their combinations can be effectively applied for 
‘euthanasia decision-making’ (103, 104). For example, body temperature changes are indicative 
of sepsis severity (130, 131) and are an independent predictor of outcome (132, 133). In large 
septic mammals, the blood glucose monitoring was reported as useful outcome predictor (134). 
Second, disease-specific parameters should be integrated into the euthanasia criteria depending 
on the type of the sepsis model used (e.g., severe dyspnea, respiratory alterations in 
pneumosepsis) (103, 104). Finally, the chosen euthanasia criteria have to be validated before use 
in each laboratory separately, for every sepsis model, species/strains, age and gender. Strong 
inter-laboratory and animal variability precludes automatic adaptation of euthanasia protocols 
across research laboratories. 
Recommendation 7: Analgesics recommended for surgical sepsis should be consistent with 
ethical considerations.  
A principle of animal welfare is that any procedure expected to cause pain in humans is 
considered likely to cause pain in animals and should be alleviated through appropriate care and 
pain management (e.g., analgesia). Regardless of international regulatory differences, surgical 
sepsis is always rated as causing the most severe grade of distress, assuming the animal recovers 
consciousness after surgery. 
The use of pre-and/or post-operative pain medicine is rarely reported in pre-clinical 
sepsis studies (115, 135). In our Wiggers-Bernard review, analgesics were used in 30 
experiments, not used in 19 and not reported in 329 experiments, despite CLP being the leading 
sepsis model. This is consistent with a recent report where only 15% of the analyzed publications 
used analgesics in experimental sepsis (61). While some (or many) of the manuscripts not 
reporting actually used analgesics, it is likely that many studies did not use analgesics in surgical 
sepsis. There are two possibilities for why investigators have historically withheld analgesia in 
surgical sepsis – a) the belief that animals cannot feel pain and/or do not feel pain based upon 
lack of signs such as vocalization, and b) the concern that analgesics would alter critical 
endpoints. The first supposition is incorrect; mice and rats demonstrate pain via changes in facial 
expression (136) and they also have subtle behavioral changes following surgery (137). This can 
be alleviated by analgesics, and trained personnel can distinguish rodents that received post-
surgical pain medicine compared to those that did not. However, mice do not typically have a 
vocal response to a painful procedure, and mice may vocalize at frequencies above the range of 
human hearing (138). 
The often-quoted reason for withholding analgesia to laboratory animals is that 
analgesics cause alterations in the inflammatory response and coagulation (139-141). It is 
important to acknowledge that different analgesics have different side effects, which may limit 
the utility of some classes of drugs in sepsis research. For instance, non-steroidal anti-
inflammatory drugs are associated with anti-inflammatory effects via inhibition of prostaglandins 
and may also be associated with renal impairment and bleeding (142). Similarly, mu-agonists 
such as morphine have immune-modulating effects and can cause respiratory depression (143). 
However, opioids that act as kappa-receptor agonists and mu-receptor antagonists have been 
demonstrated to be safe and effective without causing significant immunomodulation. 
Specifically, numerous studies have demonstrated the efficacy/safety of buprenorphine and 
tramadol (144, 145). While buprenorphine adversely may impact mortality in male (but not 
female) septic mice, this can be prevented by dose reduction (146). Furthermore, buprenorphine 
treatment results in minimal differences in inflammatory parameters although neutrophil counts 
are transiently decreased in male mice (146). In addition, continuous infusion of nalbuphine, 
another opioid agonist/antagonist, has been used in rodent models of CLP and fecal slurry (147, 
148). 
Importantly, while analgesics can alter the inflammatory profile, pain, in and of itself, may 
also affect disease outcome and experimental variability (115). Thus, from both an ethical and 
experimental standpoint, the use of analgesics should be standard and reported in surgical sepsis 
models. Exceptions – if they exist – should be rare, should be experimentally demonstrated and 
cannot be justified by the catch-all phrase that “analgesics alter the host response”. 
 
Consideration d)  Consider analgesics for nonsurgical sepsis. 
The data are less clear for animals in which sepsis is induced via a non-surgical approach. Sepsis 
clearly causes encephalopathy in patients. Many septic patients in the ICU appear to be in pain, 
although it is difficult to separate the impact of the underlying disease from interventions meant 
to support septic patients (mechanical ventilation, pressor support via large bore invasive 
catheters). Guidelines for the management of critically ill patients state that “adult medical, 
surgical and trauma ICU patients routinely experience pain, both at rest and with routine ICU 
care” and recommend intravenous opioids as the first-line drug class of choice to treat non-
neuropathic pain in critically ill patients (not specific to sepsis) (149). In the absence of clear 
data suggesting the degree to which laboratory animals with sepsis from a non-surgical source 
experience pain, investigators should weigh the benefits of analgesia versus the potential side 
effects of analgesia. Implementation of rigorous pain-oriented monitoring of septic rodents (and 
larger species) subjected to non-surgical sepsis protocols may likely provide the necessary 
evidence regarding the absence/presence of pain as well as its potential magnitude. It is possible 
that the emerging evidence will support a uniform implementation of analgesics in all septic 
models regardless of the experimental origin of sepsis. 
  
 
SUMMARY  
This Part I manuscript details the recommendations and considerations of the two working 
groups from the Wiggers-Bernard conference on pre-clinical models of sepsis. Analysis of the 
top-cited pre-clinical sepsis papers showed substantial shortcomings regarding both the use and 
reporting on the study design and humane modeling elements. Due to multiple inconsistencies 
with the clinical conditions, inadequate modeling protocols are at least partly responsible for 
failures in developing effective therapies for septic patients. Given the disease burden, the 
highest standards of animal welfare must be implemented in all pre-clinical sepsis studies. The 
two working groups made specific recommendations about the rigors of study design and 
adequate humane modeling of sepsis in animals. We hope that these recommendations and 
considerations will serve to bring a level of standardization to pre-clinical models of sepsis and 
ultimately improve the translation of pre-clinical findings. We acknowledge that new challenges 
based on new information from the clinical and bench studies will continue to arise. A close 
collaborative work between basic scientists and clinicians is critical for a thoughtful 
(re)interpretation of any existing and newly posited principles. 
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 Table 1. Study Design Endpoints in Sepsis Models (2003-2012*) 
Species Presence of 
comorbidit
y 
Mortality 
as 
endpoint 
Follow-up 5-day mortality 
  
If present, 
experimental 
treatment given 
as 
mouse:  295 
rat:   56 
pig:     7 
sheep:     5 
NHP:     4 
rabbit:     3 
cat:     1 
dog:     1 
hamster:     1 
   guinea pig:     
1 
yes:    18 
no:  356 
yes:  160 
no:  214 
       <5 days:  
143 
>5 days <14:  
154 
     >14 days:    
37 
     not stated:   
13 
high (≤70%): 142        
(>30%<70%):    
77 
low (≤30%):     
43 
not stated:     74 
pre-treatment: 96 
co-treatment: 59 
post-treatment: 95 
not stated: 13 
*Collated data is obtained from review of the 360 most-cited papers (featuring total of 374 
animal experiments) identified with ISI Web of Knowledge database (using the query:“sepsis 
model”). NHP: non-human primate. 
 
  
Table 2. Study Design Endpoints Working Group (WG): Recommendations (R) and 
Considerations (C) 
Study Design 
(WG-1) 
1.  Survival follow-up should reasonably reflect the clinical time course of the sepsis model  
2.  Therapeutic interventions should be initiated after the septic insult replicating clinical care 
 3.  We recommend that the treatment be randomized and blinded when feasible 
4.  Provide as much information as possible (e.g. ARRIVE guidelines) on the model and 
methodology, to enable replication 
R 
a.   Consider replication of the findings in models that include co-morbidity and/or other 
biological variables (i.e., age, gender, diabetes, cancer, immuno-suppression, genetic 
background and others) 
b.   In addition to rodents (mice and rats), consider modeling sepsis also in other (mammal) 
species 
c.   Consider need for source control 
C 
 
 
  
Table 3. Humane Modeling Endpoints in Sepsis Models (2003-2012*) 
Defined criteria 
for euthanasia 
given
& 
  
Analgesics used If analgesics 
used: frequency 
of application 
Full anesthesia 
throughout the duration 
of experiment 
yes:   33 
no: 341 
yes:    30 
no:    19 
not stated:  329 
1x:  14 
2-4x:    4 
>5x:    4 
continuous i.v.:    
4 
not stated:    4 
yes:     19 
        not used/not stated:   
355 
*Collated data is obtained from review of the 360 most-cited papers (featuring total of 374 
animal experiments) identified with ISI Web of Knowledge database (using the query:“sepsis 
model”). &irrespective of mortality as an endpoint. i.v.: intravenous.  
  
Table 4. Humane Modeling Endpoints Working Group (WG): Recommendations (R) and 
Considerations (C) 
Humane 
Modeling 
(WG-2) 
1.  The development and validation of standardized criteria to monitor the well-
being of septic animals is recommended 
2.  The development and validation of standardized criteria for euthanasia of septic 
animals is recommended (exceptions possible) 
        3.  Analgesics recommended for surgical sepsis should be consistent with ethical 
considerations 
R 
a.   Consider analgesics for nonsurgical sepsis C 
 
 
 
